Patents by Inventor Steven C. Quay

Steven C. Quay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Production and use of derivatized homoserine lactones
    Patent number: 7560572
    Abstract: The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are useful for treating and preventing disease states in a subject. The compositions of the invention are also useful in various assays, including assessing the autoinducer load in a subject.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: July 14, 2009
    Assignee: K-Quay Enterprises, LLC
    Inventor: Steven C. Quay
  • COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY
    Publication number: 20090118158
    Abstract: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.
    Type: Application
    Filed: September 19, 2008
    Publication date: May 7, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventor: Steven C. Quay
  • MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES
    Publication number: 20090018097
    Abstract: A double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5?-methyl-pyrimidine and/or at least one 2?-O-methyl ribonucleotide, and a method of improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA.
    Type: Application
    Filed: May 25, 2006
    Publication date: January 15, 2009
    Applicant: MDRNA, INC
    Inventors: Steven C. Quay, Kunyuan Cui, Paul H. Johnson, Lishan Chen, Mohammad Ahmadian
  • Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
    Publication number: 20080318837
    Abstract: What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.
    Type: Application
    Filed: December 1, 2006
    Publication date: December 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Henry R. Costantino, Michael V. Templin, Alexis Kays Leonard, Mary S. Kleppe, Joshua O. Sestak
  • AMINO ACID LIPIDS AND USES THEREOF
    Publication number: 20080317839
    Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Application
    Filed: May 2, 2008
    Publication date: December 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Michael Houston, JR., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Gallagher Prieve, Kathy Lynn Fosnaugh, Shaguna Seth
  • Mucosal Delivery of Stabilized Formulations of Exendin
    Publication number: 20080318861
    Abstract: What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-?-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits at least 95% exenatide recovery after storage for at least 365 days at 5° C.
    Type: Application
    Filed: December 7, 2006
    Publication date: December 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Henry R. Costantino, Alexis Kays Leonard
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING APOB GENE EXPRESSION AND USES THEREOF
    Publication number: 20080299659
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ApoB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ApoB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ApoB gene in a cell or in a subject to treat an ApoB-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: December 4, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF
    Publication number: 20080293136
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing AKT gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an AKT mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an AKT gene in a cell or in a subject to treat an AKT-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: November 27, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB GENE EXPRESSION AND USES THEREOF
    Publication number: 20080287383
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: November 20, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF
    Publication number: 20080286866
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing VEGFA, VEGFB, VEGFC, FIGF, or PGF gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a VEGF mRNA. In addition, the meroduplex may have at least one 5-methyluridine, locked nucleic acid, 2?-O-methyl, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a VEGF gene in a cell or in a subject to treat a VEGF-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: November 20, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • CYANOCOBALAMIN LOW VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY
    Publication number: 20080255067
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Application
    Filed: June 19, 2008
    Publication date: October 16, 2008
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • Compositions and methods for enhanced mucosal delivery of parathyroid hormone
    Patent number: 7435720
    Abstract: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: October 14, 2008
    Assignee: MDRNA, Inc.
    Inventors: Steven C. Quay, Henry R. Costantino, Mary S. Kleppe, Ching-Yuan Li
  • METHOD OF TREATMENT OF A METABOLIC DISEASE USING INTRANASAL ADMINISTRATION OF EXENDIN PEPTIDE
    Publication number: 20080234200
    Abstract: Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein.
    Type: Application
    Filed: May 20, 2008
    Publication date: September 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Alexis Kays Leonard, Henry R. Costantino
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Publication number: 20080182817
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Application
    Filed: March 27, 2008
    Publication date: July 31, 2008
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent number: 7404489
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: July 29, 2008
    Assignee: QOL Medical, LLC
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS
    Publication number: 20080076701
    Abstract: Dicer substrate RNA peptide conjugates comprising a double stranded ribonucleic acid (dsRNA) having a sense strand and an antisense strand, and a peptide, wherein the dicer substrate RNA is conjugated to the peptide, and compositions and methods of use thereof.
    Type: Application
    Filed: August 10, 2007
    Publication date: March 27, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Paul Hickok Johnson, Michael E. Houston, Roger C. Adami, Renata Fam
  • Phage displayed Trp cage ligands
    Patent number: 7329725
    Abstract: Trp cage binding domain polypeptides are disclosed. The Trp cage binding domains have the generic formulas of SEQ ID NO: 2, 7, 10 or 11. They can be efficiently produced and screened using phage display technology.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: February 12, 2008
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Douglas L. Badders, Richard E. Herman, Michael E. Houston, Jr., Paul Hickok Johnson
  • COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS
    Publication number: 20070276134
    Abstract: What is described is a stable double stranded (ds) nucleic acid molecule composition, comprising a dsRNA molecule complexed with an organic cation.
    Type: Application
    Filed: February 16, 2007
    Publication date: November 29, 2007
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: David S. Sweedler, Roger C. Adami, Henry R. Costantino, Steven C. Quay
  • CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
    Publication number: 20070275923
    Abstract: What is described is a composition for delivery of a RNA molecule to a cell, comprising: a double stranded RNA (dsRNA) molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L forms of arginine.
    Type: Application
    Filed: February 16, 2007
    Publication date: November 29, 2007
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Lishan Chen, Michael E. Houston, Roger C. Adami, James Anthony McSwiggen, Sasha J. Mayer, Steven C. Quay
  • COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX
    Publication number: 20070254362
    Abstract: Provided are siRNA molecules of between about 15 base-pairs and about 40 base-pairs comprising one or more universal-binding nucleotide such as inosine, 1-?-D-ribofuranosyl-5-nitroindole, and 1-?-D-ribofuranosyl-3-nitropyrrole, compositions comprising one or more universal-binding nucleotide comprising siRNA, and methods for making and for using such universal-binding nucleotide comprising siRNA molecules to increase the specific binding of the modified siRNA molecule to variants of a target sequence such as, for example, when in contact with a biological sample and to reduce off-target effects of the siRNA molecule.
    Type: Application
    Filed: December 13, 2006
    Publication date: November 1, 2007
    Inventors: Steven C. Quay, James Anthony McSwiggen